Short answer · Medically reviewed summary · Last updated: 2023-07-13
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder that affects the mitochondria, which are the energy-producing structures within cells. It is caused by mutations in the TYMP gene, which leads to the deficiency of an enzyme called thymidine phosphorylase.
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare genetic disorder that affects the mitochondria, which are the energy-producing structures within cells. It is caused by mutations in the TYMP gene, which leads to the deficiency of an enzyme called thymidine phosphorylase. This enzyme is responsible for breaking down certain molecules in the body.
The main symptoms of MNGIE include gastrointestinal problems, such as severe weight loss, diarrhea, and malabsorption of nutrients. Neurological symptoms, such as muscle weakness, peripheral neuropathy, and progressive loss of motor skills, are also common. Additionally, individuals with MNGIE may experience ophthalmoplegia (paralysis of eye muscles), hearing loss, and other systemic complications.
It is important to note that MNGIE is not contagious. It is an inherited disorder that is passed down from parents to their children. The condition follows an autosomal recessive pattern, meaning that both parents must carry a copy of the mutated gene for their child to be affected. However, even if both parents carry the gene, there is only a 25% chance of their child developing MNGIE.
Currently, there is no cure for MNGIE, but treatment options aim to manage the symptoms and improve the quality of life for affected individuals. These may include nutritional support, medications to alleviate gastrointestinal symptoms, physical therapy, and other supportive measures.